Valid Property- E nhanced C ontrastive Learning for T argeted O ptimization & R esampling for Novel Drug Design
Amartya Banerjee, Somnath Kar, Anirban Pal, Debabrata Maiti · 2025
Read Valid Property- E nhanced C ontrastive Learning for T argeted O ptimization & R esampling for Novel Drug Design by Amartya Banerjee, Somnath Kar, Anirban Pal, Debabrata Maiti (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2509-00684.txt.
Introduction
Amartya Banerjee, with three co-authors, presents VECTOR+ for drug design with scarce data. The tool steers generative models toward useful parts of chemical space. That steering is a major obstacle when training data are few. VECTOR+ aims to make the search both guided and data-efficient.
The method couples contrastive learning with controlled molecule generation. Contrastive learning pulls similar molecules together in its internal space. It works for both regression tasks and classification tasks. Tests use a PD-L1 inhibitor set and a kinase inhibitor set. Many generated candidates score better on docking than known reference drugs. Docking scores predict how strongly a molecule binds its target. Checks with molecular dynamics confirm that binding is stable.
Catalog record
| CREATOR | Amartya Banerjee, Somnath Kar, Anirban Pal, Debabrata Maiti |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2509-00684
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Valid Property- E nhanced C ontrastive Learning for T argeted O ptimization & R esampling for Novel Drug Design Amartya Banerjee, Somnath Kar, Anirban Pal, Debabrata Maiti Abstract Efficiently steering generative models toward pharmacologically relevant regions of chemical space remains a major obstacle in molecular drug discovery in the low-data regime. We present VECTOR+: V alid - property - E nhanced C ontrastive Learning for T argeted O ptimization and R esampling, a contrastive - learning and latent - sampling framework that couples property - guided representation learning with controllable molecule generation. VECTOR+ can be efficiently applied to both regression and classification tasks and enables interpretable, data-efficient exploration of functional chemical space in low-data setting. We demonstrate the method on two distinct datasets: a curated PD-L1 inhibitor set (296 compounds with experimentally determined IC 50 values) and an available receptor kinase inhibitor set (2,056 molecules categorized by binding mode). Despite limited training data, VECTOR+ successfully generates novel, synthetically tractable candidates. Against PD-L1 (PDB ID: 5J89), 100 of 8,374 generated molecules surpass a docking threshold of - 15.0 15.0 kcal/mol, with the top candidate scoring - 17.6 17.6 kcal/mol outperforming known inhibitors (best docking score: - 15.4 15.4 kcal/mol). The best-performing molecules retain the conserved biphenyl pharmacophore while introducing novel chemical motifs. 250 ns molecular dynamics simulations confirm their binding stability (ligand RMSD < 2.5 2.5 Å). VECTOR+ generalizes effectively to kinase inhibitors as well, producing compounds with superior docking scores compared to established drugs such as brigatinib and sorafenib. Benchmarking against state-of-the-art generative models, such as JT-VAE and MolGPT, across multiple metrics (docking score, novelty, uniqueness, Tanimoto similarity) demonstrates the superior performance of our method. Together, these results position our work as a robust and extensible approach for property-conditioned molecular design in low-data regime, bridging contrastive learning and generative modeling for reproducible, AI-accelerated discovery. 1 1 footnotetext: Corresponding authors: [email protected] ; [email protected] 2 2 footnotetext: These authors contributed equally. Introduction The process of discovering new therapeutics remains one of the most expensive, time-consuming, and uncertain endeavors in modern science, with costs exceeding US$2.8 billion and a duration of over 12 years for the development of a novel drug [ 1 ] . Despite decades of progress in chemistry, biology, and screening technologies, the core workflow for small-molecule drug discovery is still dominated by empirical and iterative exploration. Machine learning (ML) has emerged as a transformative tool in modern drug discovery, revolutionizing traditional approaches through data-driven decision-making [ 2 , 3 , 4 ] . The field has evolved significantly from high-throughput screening and Computer-Aided Drug Design (CADD) to the integration of artificial intelligence (AI) and ML technologies. Today, researchers across the globe are leveraging ML models at various stages of the drug discovery pipeline, including target identification and validation [ 5 ] , virtual screening, hit and lead discovery, lead optimization, quantitative structure–activity relationship (QSAR) modeling [ 6 ] , and predictive toxicology [ 7 , 8 , 9 ] . More recently, the advent of generative AI has further accelerated the progress of de novo molecular design. These approaches aim to algorithmically generate novel compounds with optimized pharmacological and physicochemical properties, thereby reducing discovery timelines and resource requirements [ 10 ] . Among the most prominent architectures explored are variational autoencoders (VAEs) [ 11 ] , generative adversarial networks (GANs) [ 12 ] , and generative pretrained transformers (GPTs) [ 13 ] , which have demonstrated promising capabilities for property-guided molecular generation and scaffold innovation. Despite recent progress in generative AI for molecular design, the application of these models to domain-specific problems in chemistry and biology remains highly constrained by limited data availability [ 14 ] . Most real-world challenges in these fields involve only a few hundred to a few thousand data points. In contrast, current generative frameworks such as VAEs, GANs, and others are typically trained on massive, general-purpose databases like ZINC, ChEMBL, or PubChem, which contain millions of diverse compounds across a wide spectrum of chemical and biological applications [ 15 , 16 ] . Consequently, when applied to a narrow, low-data regimes, these models often perform poorly, failing to capture domain-specific structure–function relationships [ 17 ] . This highlights a critical need for new generative approaches that are explicitly designed to operate effectively in data-scarce, problem-specific settings. One such application space where this need is particularly acute is cancer-targeted drug discovery, which is a longstanding priority for both academic researchers and pharmaceutical industries. Cancer is the second leading cause of death after cardiovascular diseases [ 18 , 19 ] . New cancer cases and cancer-related deaths are increasing at a steep rate with each passing year. Chemotherapy remains the widely used modality in the treatment of cancer, along with surgery, immunotherapy, and radiation therapy [ 20 , 21 ] . Although chemotherapeutic drugs are used around the world in cancer therapy, due to their non-selectivity and specificity, they result in severe side effects [ 22 , 23 ] . This underscores the critical importance of designing target-specific anticancer therapies with improved efficacy and safety profiles. Among the most promising targets are the Programmed Death-Ligand 1 (PD-L1) and protein kinase systems, both of which exhibit aberrant expression across a wide spectrum of malignancies [ 24 , 25 , 26 , 27 , 28 , 29 , 30 ] . Tumor cells evade immune surveillance by exploiting checkpoint pathways, notably the PD-1/PD-L1 axis, where PD-L1 binding to PD-1 leads to T cell dysfunction and tumor progression. Blocking this interaction restores T cell activity and enhances antitumor immunity [ 31 ] . The kinase receptor system, on the other hand, particularly receptor tyrosine kinases (RTKs), contributes to tumor growth by transmitting signals that drive cell proliferation, survival, migration, and angiogenesis [ 32 ] . Hence, the design of inhibitors against these targets helps to inhibit cancer progression and metastasis. In this work, we present a generative modeling framework tailored for the design of new small-molecule inhibitors targeting PD-L1 and kinase receptors. Our full code and data is available at https://github.com/amartya21/vector-drug-design.git . Our major contributions are as follows: • We propose a new method VECTOR+ which addresses the critical challenge of data scarcity by structuring the chemical latent space according to biological function. This enables meaningful representation learning from limited datasets, a common bottleneck in drug discovery. Furthermore, we ground our approach in a classical result by leveraging a fundamental principle of information theory that moment-matching Gaussians uniquely minimize forward KL divergence. This principle provides a strong rationale for our use of GMM-based sampling, validating VECTOR+ as a mathematically principled framework for latent space modeling. • We validate our method on PD-L1 and Kinase inhibitor datasets. This leads to a high yield of novel candidates and has produced a PD-L1 inhibitor with a significantly high docking score of -17.6 kcal/mol, surpassing known compounds. For kinase inhibitors, starting with just 47 allosteric inhibitor training molecules, we successfully generated 2,500 novel, drug-like compounds with high validity and uniqueness. • The proposed framework is broadly generalizable and can be readily extended to accelerate drug discovery across diverse therapeutic targets and molecular generation domains. While the method demonstrates strong performance in extremely low-data regimes, the framework is equally applicable when larger training datasets